J&J Risperdal, Topamax Are Candidates For Alza Drug Delivery Systems
Executive Summary
Johnson & Johnson's antipsychotic Risperdal and anti-epileptic agent Topamax are candidates for product life extension through Alza's drug delivery technology (especially the OROS osmotic system), Alza Pharmaceuticals Group VP Samuel Saks, MD, told analysts March 27.
You may also be interested in...
J&J Antipsychotic Paliperidone ER Moves Into Phase III
Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies
J&J Antipsychotic Paliperidone ER Moves Into Phase III
Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies
Alza Delivery Technologies Reduce Drug Enhancement Costs To $80 Mil.
Alza drug delivery technologies reduce the cost of developing an enhanced version of an already-marketed drug to $70 mil.-$80 mil., Alza Chairman Sam Saks, MD, said during Johnson & Johnson's business review Sept. 23